{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:27Z","timestamp":1793727747389,"version":"4.6.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.blre.2021.100910","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T16:32:12Z","timestamp":1637425932000},"page":"100910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities"],"prefix":"10.1016","volume":"53","author":[{"given":"Tali","family":"Siegal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Benouaich-Amiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osnat","family":"Bairey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2021.100910_bb0005","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood-2016-09-670224","article-title":"Myeloid malignancies and the microenvironment","volume":"129","author":"Korn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100910_bb0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100910_bb0015","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Ocn, Hammond L, Ogba N: acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2021.100910_bb0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2021.100910_bb0025","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26079","article-title":"Determination of fitness and therapeutic options in older patients with acute myeloid leukemia","volume":"96","author":"Cortes","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100910_bb0030","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood.2019001982","article-title":"How I treat relapsed or refractory AML","volume":"136","author":"DeWolf","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100910_bb0035","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2021.100910_bb0040","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1200\/JCO.2016.67.5892","article-title":"Extramedullary disease in adult acute myeloid leukemia is common but lacks independent significance: analysis of patients in ECOG-ACRIN Cancer research group trials, 1980-2008","volume":"34","author":"Ganzel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100910_bb0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.wneu.2021.01.004","article-title":"Treatment outcomes of intracranial myeloid sarcomas: a Meta-analysis","volume":"148","author":"Lee","year":"2021","journal-title":"World Neurosurg"},{"key":"10.1016\/j.blre.2021.100910_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2019.04.019","article-title":"Neuroleukemiosis: Diagnosis and management","volume":"184","author":"Mau","year":"2019","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.blre.2021.100910_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/CMAR.S125259","article-title":"Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia","volume":"9","author":"Alakel","year":"2017","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.blre.2021.100910_bb0060","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12885-015-1376-9","article-title":"Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults","volume":"15","author":"Cheng","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2021.100910_bb0065","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3109\/10428194.2014.953148","article-title":"Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia","volume":"56","author":"Rozovski","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2021.100910_bb0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.26253","article-title":"Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease","volume":"118","author":"Shihadeh","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2021.100910_bb0075","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/ejh.13314","article-title":"Impact of central nervous system involvement in AML on outcomes after allotransplant and utility of pretransplant cerebrospinal fluid assessment","volume":"103","author":"Prem","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100910_bb0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.seminhematol.2018.02.006","article-title":"Involvement of central nervous system in adult patients with acute myeloid leukemia: incidence and impact on outcome","volume":"55","author":"Del Principe","year":"2018","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2021.100910_bb0085","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.bbmt.2014.11.683","article-title":"Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation","volume":"21","author":"Bar","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100910_bb0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12253-016-0162-6","article-title":"Central nervous system involvement at the time of allogeneic hematopoietic stem cell transplantation is associated with a poor outcome in patients with acute myeloid leukemia","volume":"23","author":"Ikegawa","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.blre.2021.100910_bb0095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijrobp.2010.01.062","article-title":"Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement","volume":"80","author":"Mayadev","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.blre.2021.100910_bb0100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/ajh.24799","article-title":"Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia","volume":"92","author":"Jabbour","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2021.100910_bb0105","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0002-9343(87)90756-X","article-title":"Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission","volume":"83","author":"Peterson","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.blre.2021.100910_bb0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.21037\/atm-20-3140","article-title":"A narrative review of central nervous system involvement in acute leukemias","volume":"9","author":"Deak","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.blre.2021.100910_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106480","article-title":"The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement","volume":"100","author":"Bergstrom","year":"2021","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2021.100910_bb0120","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26612","article-title":"Central nervous system disease in pediatric acute myeloid leukemia: a report from the Children\u2019s oncology group","volume":"64","author":"Johnston","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2021.100910_bb0125","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.V65.5.1071.1071","article-title":"A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22)","volume":"65","author":"Holmes","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100910_bb0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.anorl.2013.09.003","article-title":"Nizam Pfeilsticker L: bilateral peripheral facial palsy and mastoid infiltration as symptoms of relapsed acute myeloid leukemia","volume":"132","author":"Leite da Silveira","year":"2015","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"10.1016\/j.blre.2021.100910_bb0135","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100910_bb0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/16078454.2020.1781500","article-title":"Zhou, Li L, ye X, Xie W: the diagnostic and prognostic value of MRI in central nervous system involvement of acute myeloid leukemia: a retrospective cohort of 84 patients","volume":"25","author":"Shen","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2021.100910_bb0145","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.4103\/2152-7806.111304","article-title":"Carcinomatous meningitis: Leptomeningeal metastases in solid tumors","volume":"4","author":"Le Rhun","year":"2013","journal-title":"Surg Neurol Int"},{"key":"10.1016\/j.blre.2021.100910_bb0150","first-page":"00026","article-title":"Cerebrospinal fluid (CSF) directed antineoplastic agents: a review of current knowledge","volume":"2","author":"Molander","year":"2015","journal-title":"J Cancer Prev Curr Res"},{"key":"10.1016\/j.blre.2021.100910_bb0155","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ijrobp.2014.08.004","article-title":"Comprehensive craniospinal radiation for controlling central nervous system leukemia","volume":"90","author":"Walker","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.blre.2021.100910_bb0160","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00277-020-04380-0","article-title":"Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia","volume":"100","author":"Chen","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2021.100910_bb0165","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.bbmt.2008.07.002","article-title":"Kanto study Group for Cell T: central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Oshima","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100910_bb0170","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1179\/1607845413Y.0000000117","article-title":"Tailored central nervous system-directed treatment strategy for isolated CNS recurrence of adult acute myeloid leukemia","volume":"19","author":"Zheng","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2021.100910_bb0175","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.leu.2404491","article-title":"Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients","volume":"21","author":"Pileri","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2021.100910_bb0180","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G","article-title":"Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases","volume":"48","author":"Neiman","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2021.100910_bb0185","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/jcm4051102","article-title":"Intracranial CNS manifestations of myeloid sarcoma in patients with acute myeloid leukemia: review of the literature and three case reports from the Author\u2019s institution","volume":"4","author":"Cervantes","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2021.100910_bb0190","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s10067-020-05167-4","article-title":"Epidural myeloid sarcoma as the presenting symptom of chronic myeloid leukemia blast crisis","volume":"39","author":"Slouma","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.blre.2021.100910_bb0195","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ejh.12085","article-title":"Extramedullary disease in patients with acute myeloid leukemia assessed by 18F-FDG PET","volume":"90","author":"Cribe","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100910_bb0200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/2040620711410774","article-title":"Myeloid sarcoma: current approach and therapeutic options","volume":"2","author":"Avni","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2021.100910_bb0205","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.3892\/ol.2017.6620","article-title":"Clinicoradiological characteristics, management and prognosis of primary myeloid sarcoma of the central nervous system: a report of four cases","volume":"14","author":"Yang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.blre.2021.100910_bb0210","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00256-015-2151-3","article-title":"Tumefactive appearance of peripheral nerve involvement in hematologic malignancies: a new imaging association","volume":"44","author":"Capek","year":"2015","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.blre.2021.100910_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113272","article-title":"Biology of the human blood-nerve barrier in health and disease","volume":"328","author":"Ubogu","year":"2020","journal-title":"Exp Neurol"},{"key":"10.1016\/j.blre.2021.100910_bb0220","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12185-020-02976-w","article-title":"(18)FDG-PET imaging and histopathology in neuroleukemiosis with acute myeloid leukemia","volume":"112","author":"Kiyoki","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2021.100910_bb0225","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420985323","article-title":"Paraneoplastic neurological syndromes: clinical presentations and management","volume":"14","author":"Devine","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.blre.2021.100910_bb0230","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1182\/blood-2014-10-551507","article-title":"How I treat hyperleukocytosis in acute myeloid leukemia","volume":"125","author":"Rollig","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100910_bb0235","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.blre.2012.01.003","article-title":"Hyperleukocytosis, leukostasis and leukapheresis: practice management","volume":"26","author":"Ganzel","year":"2012","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2021.100910_bb0240","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.1365-2141.1997.1943011.x","article-title":"Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate","volume":"98","author":"Porcu","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2021.100910_bb0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-015-0387-8","article-title":"Management of Hyperleukocytosis","volume":"17","author":"Ruggiero","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.blre.2021.100910_bb0250","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.leukres.2014.01.004","article-title":"Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis","volume":"38","author":"Oberoi","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2021.100910_bb0255","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/trf.15994","article-title":"Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-a systematic review and meta-analysis","volume":"60","author":"Bewersdorf","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2021.100910_bb0260","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1741-7015-10-97","article-title":"Intracranial hemorrhage in adult patients with hematological malignancies","volume":"10","author":"Chen","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.blre.2021.100910_bb0265","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdn755","article-title":"Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia","volume":"20","author":"Chen","year":"2009","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2021.100910_bb0270","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.thromres.2018.01.041","article-title":"Mechanisms and management of coagulopathy in acute promyelocytic leukemia","volume":"164","author":"David","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2021.100910_bb0275","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1080\/10428194.2019.1581187","article-title":"Predictors of early hemorrhage in acute promyelocytic leukemia","volume":"60","author":"Naymagon","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2021.100910_bb0280","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0049-3848(20)30399-6","article-title":"Advances in the management of coagulopathy in acute promyelocytic leukemia","volume":"191","author":"Sanz","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2021.100910_bb0285","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1055\/s-0030-1267045","article-title":"Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia","volume":"36","author":"Kwaan","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2021.100910_bb0290","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1055\/s-0039-1693478","article-title":"The role of abnormal hemostasis and fibrinolysis in morbidity and mortality of acute Promyelocytic leukemia","volume":"45","author":"Kwaan","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2021.100910_bb0295","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood-2016-09-739334","article-title":"Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia","volume":"129","author":"Cao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100910_bb0300","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2016-10-747170","article-title":"Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era","volume":"129","author":"Mantha","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100910_bb0305","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100910_bb0310","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.thromres.2014.11.026","article-title":"Thrombotic events in acute promyelocytic leukemia","volume":"135","author":"Mitrovic","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2021.100910_bb0315","series-title":"Neurotoxicity of Cancer Therapies Continuum (Minneap Minn)","first-page":"1646","volume":"26","author":"Dietrich","year":"2020"},{"key":"10.1016\/j.blre.2021.100910_bb0320","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.rcl.2021.01.008","article-title":"Imaging of neurologic injury following oncologic therapy","volume":"59","author":"Ouyang","year":"2021","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.blre.2021.100910_bb0325","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/bmt.2017.239","article-title":"Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact","volume":"53","author":"Dowling","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100910_bb0330","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.bbmt.2007.07.013","article-title":"Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance","volume":"13","author":"Siegal","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100910_bb0335","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4103\/1673-5374.233431","article-title":"Neurological complications of hematopoietic cell transplantation in children and adults","volume":"13","author":"Dulamea","year":"2018","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.blre.2021.100910_bb0340","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.bbmt.2016.12.632","article-title":"Neurologic complications after allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Maffini","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100910_bb0345","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1002\/acn3.50909","article-title":"Neurologic complications after allogeneic transplantation: a meta-analysis","volume":"6","author":"Gavriilaki","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.blre.2021.100910_bb0350","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.bbmt.2019.05.024","article-title":"Noninfectious neurologic complications after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Balaguer-Rosello","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2021.100910_bb0355","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000499651","article-title":"Central nervous system complications after allogeneic hematopoietic stem cell transplantation in children","volume":"142","author":"Ke","year":"2019","journal-title":"Acta Haematol"},{"issue":"8","key":"10.1016\/j.blre.2021.100910_bb0360","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2021.100910_bb0365","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.clml.2015.11.018","article-title":"Pseudotumor Cerebri in acute Promyelocytic leukemia patients on intergroup protocol 0129: clinical description and recommendations for new diagnostic criteria","volume":"16","author":"Coombs","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2021.100910_bb0370","article-title":"All-trans retinoic acid-induced Pseudotumor Cerebri during induction therapy for acute Promyelocytic leukemia: a case report and literature review","volume":"2012","author":"Holmes","year":"2012","journal-title":"Case Rep Oncol Med"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21001168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21001168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:28:20Z","timestamp":1759436900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21001168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":74,"alternative-id":["S0268960X21001168"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100910","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100910"}}